Table 1 Patient, tumour and treatment characteristics (N = 26)
From: Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
Age (median, range) | 52 (34-66) |
Sex (Female) | 42% |
Ethnicity | Asian 31%, Caucasian 69% |
Smoking status | Never 58%, light (<10-pyHx) 15%, heavy (>10pyHx) 27% |
Diagnosis | Stage IV 96%, confirmed Adenocarcinoma 96%. ALK FISH rearranged: 92%. |
Crizotinib provision | Trial: 69%, Access scheme: 31% |
Crizotinib duration (median, range weeks) | 58 (22-240) |
Crizotinib as line of treatment | 1st 34%, 2nd 31%, 3rd 27%, 4th 0%, 5th 8%. |
Best radiological response | PD 0%, SD 12%, PR 73%, CR 15% |